drugset / Trial / NCT06193811

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

NCT06193811

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate: * the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs. Avenciguat (BI 685509) iCF (Test 1, T1) tablets under fasted conditions * the relative bioavailability of Avenciguat (BI 685509) iCF tablets under fasted (T1) and fed (Test 2, T2) conditions * the relative bioavailability of Avenciguat (BI 685509) iCF tablets given alone (T1) and together with esomeprazole (Test 3, T3) under fasted conditions

Timeline

Start
2024-01-16
Primary completion
2024-03-14
Completion
2024-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Avenciguat Small molecule Oral
Subject Esomeprazole Small molecule Oral

Indications

No indication recorded.